# Remifemin Preventing the Climacteric Symptoms in Breast Cancer

> **NCT03339882** · PHASE2 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 85 (actual)

## Conditions studied

- Effect of Drugs
- Safety Issues

## Interventions

- **DRUG:** Remifemin

## Key facts

- **NCT ID:** NCT03339882
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-04
- **Primary completion:** 2017-11-27
- **Final completion:** 2018-01-30
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2018-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03339882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03339882, "Remifemin Preventing the Climacteric Symptoms in Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03339882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*